profit from every £100 of sales.
£0£100
Oxford Biomedica
£5.35-3.60% today
-12.2% in 1 year
1-year low £4.241-year high £9.13
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Oxford Biomedica sold, what it kept, and what it did with the cash.
Sales went from £140 million in 2022 to £169 million in 2025, with -£30.1 million of profit last year.
SalesProfit
Oxford Biomedica vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Oxford Biomedica | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Oxford Biomedica's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 140 | 90 | 129 | 169 | |
| 69 | 40 | 53 | 66 | |
| -52 | -88 | -44 | -33 | |
| -11 | -149 | -14 | 2 | |
| -39 | -157 | -43 | -30 | |
| -0.41 | -1.63 | -41.75 | -0.27 | |
| 49.4% | 44.4% | 41.2% | 39.1% | |
| -36.8% | -98.4% | -33.8% | -19.5% | |
| -28.0% | -175.9% | -33.5% | -17.9% |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 460 | 252 | 232 | 326 |
| Cash | 141 | 104 | 61 | 97 |
| Total debt | 114 | 111 | 109 | 148 |
| Total liabilities | 224 | 175 | 171 | 234 |
| 205 | 74 | 57 | 91 | |
| 95 | 97 | 103 | 112 | |
| -8.8% | -71.7% | -16.6% | -5.5% | |
| -19.1% | -212.8% | -75.7% | -33.0% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -13 | -29 | -51 | 1 | |
| 16 | 10 | 7 | 5 | |
| -29 | -38 | -58 | -4 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 6 | 4 | 2 | 5 |
Valuation
- –
- –
- –
- 8.1×
- 3.9×
- –
- 290.6×
- -0.7%
- -4.6%
- –
Profitability
- 39.1%
- -19.5%
- -17.9%
- –
- -5.5%
- -25.6%
- –
- –
- –
- –
Growth
- +6.4%
- –
- –
- –
- +5.7%
Financial health
- 21.2×
- 1.62
- –
- -1.2×
- 2.20
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 952
Bottom 12%of 883
Bottom 32%of 870
Bottom 35%of 985
News
Oxford Industries declares $0.70 dividendSeeking Alpha · Sep 4, 2026The newest story we have is from Sep 4, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
12No pass
Benjamin Graham
23No pass
Philip Fisher
19No pass
Peter Lynch
24No pass
Joel Greenblatt
0No pass
Charlie Munger
13No pass
Terry Smith
15No pass
Questions about Oxford Biomedica
Is Oxford Biomedica a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Oxford Biomedica AI analysis
What does Oxford Biomedica do?
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. It is in Biotechnology, based in Oxford, United Kingdom, with 977 employees.
Is Oxford Biomedica stock halal?
Yes. Oxford Biomedica passes our halal screen: its business is permitted and its debt is 23% of its market value, under the 30% limit. How we check
How has Oxford Biomedica stock done over the past year?
Down 12.2% over the past twelve months, to £5.35. It traded between £4.24 and £9.13 and is 41.4% below its high.
Who are Oxford Biomedica's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Oxford Biomedica's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.